A move from ~ $0.022 to ~ $0.0335 is about a 50% increase. That's more than nothing, and much easier for me to stomach.
I agree, we should have been at $0.10 or higher, but we weren't because of the unknown dilution to pay the convertible debt and because of the unknown dilution related to the S-1 offering. Those numbers are known now and far better than I was estimating, but the dilution is still significant, so that is the focus.
That, and Iliad was given 60 days to sell all shares that they or their associates are holding, after which they are forbidden to own RXMD stock for 3 years. So they are liquidating as required. Who knows what games they were playing, but there are non-disparagement and agreements not to sue each other in place, so we'll never know.
What isn't being considered by the market is the significant cash that is now in hand to implement the technology expansion plan, which is being implemented and will be marketed by our new majority shareholder partners, that happen to be technology and healthcare experts.
I didn't expect an instant rise to $0.10 or better on the news, but I do expect it will happen. It isn't happening on the timeline that I expected in 2021, but I believe that it will happen before the February 2023 uplisting deadline. No matter what anyone thinks about that timeline, they should also acknowledge that the future is far brighter than we expected last month. It took time to finalize, but stockforce has shared the paper trail that shows that this is the deal that was in the works since the S-1 was filed.
At this point, I'm comfortable and just waiting for the pieces to fall into place.
Good Luck to Us!
Go RXMD!
News 
Market Data 
Discover 
